menu
    • menu
    [{"orgOrder":0,"company":"IDRx","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Acquisition","leadProduct":"IDRX-42","moa":"TYK","graph1":"Oncology","graph2":"Phase I","graph3":"IDRx","amount2":1.1499999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":1.1499999999999999,"dosageForm":"Oral Tablet","sponsorNew":"IDRx \/ GSK","highestDevelopmentStatusID":"6","companyTruncated":"IDRx \/ GSK"},{"orgOrder":0,"company":"IDRx","sponsor":"Andreessen Horowitz","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Series A Financing","leadProduct":"IDRX-42","moa":"TYK","graph1":"Gastroenterology","graph2":"Phase I","graph3":"IDRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IDRx \/ Andreessen Horowitz","highestDevelopmentStatusID":"6","companyTruncated":"IDRx \/ Andreessen Horowitz"},{"orgOrder":0,"company":"IDRx","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series B Financing","leadProduct":"IDRX-42","moa":"TYK","graph1":"Oncology","graph2":"Phase I","graph3":"IDRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IDRx \/ RA Capital Management","highestDevelopmentStatusID":"6","companyTruncated":"IDRx \/ RA Capital Management"},{"orgOrder":0,"company":"IDRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"IDRX-42","moa":"TYK","graph1":"Oncology","graph2":"Phase I","graph3":"IDRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IDRx \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"IDRx \/ Inapplicable"},{"orgOrder":0,"company":"IDRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"IDRX-42","moa":"TYK","graph1":"Oncology","graph2":"Phase I","graph3":"IDRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IDRx \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"IDRx \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for [4-(Methyl-1H-pyrazol-4-yl)-benzyl] -(6-[7-(3-pyrrolidin-1-yl-propoxy)-imidazo[1,2-a] pyridin-3-yl]-pyrimidin-4-yl]-amine

    Menu

    [4-(Methyl-1H-pyrazol-4-yl)-benzyl] -(6-[7-(3-pyrrolidin-1-yl-propoxy)-imidazo[1,2-a] pyridin-3-yl]-pyrimidin-4-yl]-amine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            IDRx

                            U.S.A arrow
                            Interphex
                            Not Confirmed

                            IDRx

                            U.S.A arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IDRX-42

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : GSK

                            Deal Size : $1,150.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            GSK Enters Agreement to Acquire IDRx, Inc.

                            Details : Through this acquisition, GSK will expand its gastrointestinal cancer portfolio with IDRX-42. IDRX-42 is a highly selective KIT TKI developed for treating gastrointestinal stromal tumors.

                            Product Name : IDRX-42

                            Product Type : Other Small Molecule

                            Upfront Cash : $1,000.0 million

                            January 13, 2025

                            Lead Product(s) : IDRX-42

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : GSK

                            Deal Size : $1,150.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            IDRx

                            U.S.A arrow
                            BioTrinity 2025
                            Not Confirmed

                            IDRx

                            U.S.A arrow
                            BioTrinity 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IDRX-42

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            IDRx Shares Phase 1 Data for IDRX-42 in Advanced GIST at CTOS 2024

                            Details : IDRX-42 is a novel, KIT inhibitor that has potent activity against both the key activating mutations and broad coverage of the clinically relevant resistance mutations in KIT-driven GIST.

                            Product Name : IDRX-42

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            November 14, 2024

                            Lead Product(s) : IDRX-42

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            IDRx

                            U.S.A arrow
                            BioTrinity 2025
                            Not Confirmed

                            IDRx

                            U.S.A arrow
                            BioTrinity 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IDRX-42

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : RA Capital Management

                            Deal Size : $120.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            IDRx Announces $120M Series B to Advance New Treatment for Gastrointestinal Stromal Tumor

                            Details : The proceeds will support the ongoing clinical trial of its lead product IDRX-42l, targeting all major categories of activating & resistance mutations in patients with KIT-mutant GIST.

                            Product Name : IDRX-42

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            July 08, 2024

                            Lead Product(s) : IDRX-42

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : RA Capital Management

                            Deal Size : $120.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            IDRx

                            U.S.A arrow
                            BioTrinity 2025
                            Not Confirmed

                            IDRx

                            U.S.A arrow
                            BioTrinity 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IDRX-42

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            IDRx Updates Phase 1 Data Supporting IDRX-42 in GIST Patients

                            Details : IDRX-42 is a novel, KIT inhibitor that has potent activity against both the key activating mutations and broad coverage of the clinically relevant resistance mutations in KIT-driven GIST.

                            Product Name : IDRX-42

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 06, 2024

                            Lead Product(s) : IDRX-42

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            IDRx

                            U.S.A arrow
                            BioTrinity 2025
                            Not Confirmed

                            IDRx

                            U.S.A arrow
                            BioTrinity 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IDRX-42

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase I

                            Sponsor : Andreessen Horowitz

                            Deal Size : $122.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            IDRx Launches with $122 Million Series A Financing to Treat Cancer with Purpose-Built Precision Combination Th...

                            Details : IDRx’s pipeline includes IDRX-42 and IDRX-73, small molecule tyrosine kinase inhibitors acquired through license agreements with Merck KGaA, Darmstadt, Germany, and Blueprint Medicines, respectively.

                            Product Name : IDRX-42

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            February 08, 2022

                            Lead Product(s) : IDRX-42

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase I

                            Sponsor : Andreessen Horowitz

                            Deal Size : $122.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth